News release

25 March 2008

World Tuberculosis Day at the NYSE

from left to right: Noreen Culhane, Executive Vice President, New York Stock Exchange; Giorgio Roscigno, CEO of FIND; Jorge Sampaio, UN Special Envoy to Stop TB; and Edward J. Ludwig, BD Chairman, President, and CEO, gathered to Ring The Closing Bell^SM on World TB Day

The New York Stock Exchange highlighted World TB Day on 24 March by inviting Dr. Jorge Sampaio, the UN Secretary General's Special Envoy to Stop TB, Dr. Edward J. Ludwig, Chairman, President and CEO of BD (Becton, Dickinson and Company), and Dr. Giorgio Roscigno, CEO of FIND (Foundation for Innovative New Diagnostics) to ring the closing bell.

Earlier on the same day, Dr. Sampaio, along with senior representatives from the US Centers for Disease Control and Prevention, Global Health Council, FIND, and BD participated in a roundtable discussion at Columbia University under the theme "TB Today: Old Enemy, New Hurdles". About 100 people attended the event, which was moderated by John Rennie, of the Scientific American.

Mr. Rennie summarized the event by describing the global TB situation with two words: urgency and dignity. All of the panellists agreed that 2008 is the year to step up advocacy efforts around implementation of the Global Plan to Stop TB.

More information on World TB Day activities can be found on the Stop TB Partnership's World TB Day website.

Click here for footage of the NYSE closing bell.

BECTON, DICKINSON AND COMPANY (NYSE: BDX):
BD, a leading medical technology company that manufactures and sells medical devices, instrument systems and reagents, is dedicated to improving people’s health throughout the world. BD is focused on making improvements in drug therapy, enhancing the quality and speed of diagnosing infectious diseases, and advancing research and discovery of new drugs and vaccines. The Company’s capabilities are instrumental in combating many of the world’s most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs approximately 28,000 people in approximately 50 countries. The Company serves healthcare institutions, life science researchers, clinical laboratories, industry and the general public. For more information, please visit the website.

FIND:
The Foundation for Innovative New Diagnostics is a non-profit Swiss foundation based in Geneva. Its purpose is to support and promote the health of people in developing countries by sponsoring the development and introduction of new but affordable diagnostic tools for poverty related diseases through public-private partnerships. FIND’s current donors include the Bill & Melinda Gates Foundation, the European Union and the Dutch Government. FIND is ISO 9001 and ISO 13485 certified.

STOP TB PARTNERSHIP:
The Stop TB Partnership was established in 2000 to eliminate tuberculosis as a public health problem and ultimately to realize a world free of TB. It comprises a network of more than 500 international organizations, countries, donors from the public and private sectors, and nongovernmental and governmental organizations that have expressed an interest in working together to achieve this goal.

Print this page  Add to favorites  Send to a friend

---

© Foundation for Innovative New Diagnostics 2008. Click here to see the copyright notice